Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

Executive Summary

Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.

You may also be interested in...



No Cash Boost For Novartis From Sandoz Spin-Off

After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.

The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?

INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022. 

Alcon Buys Aerie, Reaffirming Commitment To Pharma Space

With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel